Compounded Peptides and the 503A/503B Landscape in 2026

The compounding pharmacy framework governing peptide prescribing in the United States is in active flux. For clinicians who prescribe compounded peptides — or who advise patients who use them — understanding the current regulatory architecture is not optional. The distinctions between 503A and 503B facilities, the FDA’s Category system for bulk substances, and the pending PCAC review have direct implications for prescribing practice.

This article provides a structured briefing on the 2026 regulatory landscape.

The Foundational Framework: DQSA 2013

The Drug Quality and Security Act (DQSA) of 2013 established the two-tier compounding regulatory structure still in effect today. It was enacted primarily in response to the 2012 meningitis outbreak linked to New England Compounding Center, which killed 64 patients.

Section 503A codified traditional compounding pharmacies — small-scale, patient-specific, state-regulated with some FDA oversight.

Section 503B created a new category: “outsourcing facilities” — large-scale compounders operating under FDA’s cGMP standards, capable of producing batch quantities for health systems and clinics without individual patient prescriptions.

503A vs. 503B: The Clinical Distinction

	503A Compounding Pharmacy	503B Outsourcing Facility
Primary regulator	State pharmacy board + FDA (limited)	FDA (cGMP inspection)
Scale	Patient-specific, small batch	Large batch, can supply clinics
Prescription required	Yes — individual patient prescription	Not required (office stock)
Oversight level	Lower — state-primary	Higher — cGMP, federally inspected
Peptide compounding (2026)	Possible if substance is on 503A Bulks List or in Category 1 interim zone	Essentially none — no peptides approved for 503B

For most telehealth-based peptide prescribing, 503A compounding pharmacies are the relevant entity. The physician generates a patient-specific prescription; the 503A pharmacy compounds the specific formulation (e.g., BPC-157 5mg/vial lyophilized powder) for that patient.

The 503A Bulk Substance Category System

The FDA evaluates bulk drug substances (APIs) used in compounding through a nomination and review process. Substances are placed in one of three categories:

Category 1: Under evaluation; compounding is generally permitted under an interim enforcement policy while the FDA conducts its review. This is the most permissive status and where most research peptides currently in circulation exist.

Category 2: FDA has determined compounding presents significant safety concerns; compounding is prohibited under the interim policy. This status is enforceable.

Category 3: Insufficient safety and efficacy data to evaluate; compounding is generally not permitted.

The final 503A Bulks List contains substances formally approved for compounding. Most peptides are not on this list — they’re in Category 1 (permitted under interim policy) or not nominated at all.

April 2026 Category Changes: What Happened

A significant regulatory event occurred in April 2026: the FDA removed approximately 12 peptides from Category 2 — including BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV, and several others — after the original nominators withdrew their petitions.

Critically, this removal did not authorize compounding. It moved these substances from an explicitly prohibited category back to an unevaluated status. Under current FDA policy, unevaluated substances that are not on the 503A Bulks List or in Category 1 are not authorized for compounding under the interim policy.

This created genuine regulatory ambiguity: BPC-157 and TB-500 are no longer in “significant safety concerns” territory, but they also aren’t affirmatively permitted. Compounders and prescribers are navigating this gray zone.

The July 23–24, 2026 PCAC Review: The Next Critical Milestone

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory committee of independent experts that evaluates bulk substances nominated for the 503A Bulks List. PCAC meetings are public; recommendations are non-binding but typically followed by the FDA.

The July 23–24, 2026 PCAC meeting is scheduled to review the following substances for possible addition to the 503A Bulks List:

BPC-157
TB-500 (Thymosin Beta-4 1-4, or related fragment)
KPV
Semax
Epitalon
MOTS-c
GHK-Cu (Copper peptide)
Melanotan II
Additional nominated substances TBD

PCAC outcomes for each substance typically follow one of four paths:

Recommended for the 503A Bulks List — affirmative green light for compounding with conditions
Not recommended — FDA likely follows with Category 2 or prohibition
Deferred for additional data — limbo continues
Removed from consideration — status quo remains unclear

For prescribers who currently offer BPC-157 or TB-500 through compounding pharmacies, the July 2026 PCAC outcomes are likely the most consequential regulatory development since DQSA.

The GLP-1 Agonist Situation: A Case Study in 503B Exclusion

The semaglutide and tirzepatide compounding controversy illustrates how quickly the regulatory landscape can shift. During the documented FDA drug shortage (2023–2025), 503A compounders were permitted to compound these agents under shortage provisions. FDA determined the shortage resolved:

Semaglutide: 503A compounding prohibition effective approximately April 2025
Tirzepatide: Prohibition proposed April 2026

This left patients on compounded GLP-1s — often at significantly lower cost than branded products — without their existing source. The litigation response was immediate and ongoing: multiple compounding pharmacy associations filed suit challenging FDA’s shortage determination methodology.

The practical upshot for clinicians: compounded semaglutide and tirzepatide in standard formulations are prohibited for new prescriptions. Novel formulations (different routes, specific patient medical need) may have a narrower exception path, but this requires careful legal analysis.

Prescribing in the Current Environment: Risk Framework

Clinicians prescribing compounded peptides should maintain a working risk framework:

Lower regulatory risk:

Substances on the 503A Bulks List or affirmatively in Category 1
Sourced from licensed 503A compounders in the patient’s state or holding appropriate out-of-state licenses
Patient-specific prescriptions with documented clinical rationale

Higher regulatory risk:

Substances in Category 2 or ambiguous post-April 2026 removal status
Compounders unable to provide documentation of FDA registration status and cGMP compliance
Office stock from sources not compliant with 503B facility requirements

Due diligence checklist for compounding pharmacy evaluation:

Confirm state pharmacy board licensure in patient’s state
Confirm FDA registration status (NABP e-Profile, FDA facility registration database)
Request current COA (lot-matched, third-party HPLC + mass spec) for any compounded peptide
Document clinical rationale for compounded vs. commercially available alternative when applicable

State Variation

Compounding law is substantially state-specific. State pharmacy boards vary in their enforcement priorities and interpretations of permitted substances. Prescribers in some states have more latitude; others have stricter rules than FDA’s floor. Always consult your state pharmacy board’s position on specific substances in addition to FDA guidance.

Conclusion

The compounded peptide regulatory environment in 2026 is at a genuine inflection point. The April 2026 Category changes created ambiguity for some of the most widely prescribed research peptides; the July 2026 PCAC review will resolve much of it. Clinicians who prescribe or recommend these compounds need to stay current on PCAC outcomes and FDA policy updates.

For up-to-date regulatory tracking, bookmark:

This article is for educational and informational purposes only. It does not constitute legal or medical advice. Prescribers should consult with legal counsel and remain current with state pharmacy board guidance for compliance decisions in their jurisdiction.

Sources